Long-Term Accumulation, Biological Effects and Toxicity of BSA-Coated Gold Nanoparticles in the Mouse Liver, Spleen, and Kidneys

Int J Nanomedicine. 2024 May 8:19:4103-4120. doi: 10.2147/IJN.S443168. eCollection 2024.

Abstract

Introduction: Gold nanoparticles are promising candidates as vehicles for drug delivery systems and could be developed into effective anticancer treatments. However, concerns about their safety need to be identified, addressed, and satisfactorily answered. Although gold nanoparticles are considered biocompatible and nontoxic, most of the toxicology evidence originates from in vitro studies, which may not reflect the responses in complex living organisms.

Methods: We used an animal model to study the long-term effects of 20 nm spherical AuNPs coated with bovine serum albumin. Mice received a 1 mg/kg single intravenous dose of nanoparticles, and the biodistribution and accumulation, as well as the organ changes caused by the nanoparticles, were characterized in the liver, spleen, and kidneys during 120 days.

Results: The amount of nanoparticles in the organs remained high at 120 days compared with day 1, showing a 39% reduction in the liver, a 53% increase in the spleen, and a 150% increase in the kidneys. The biological effects of chronic nanoparticle exposure were associated with early inflammatory and fibrotic responses in the organs and were more pronounced in the kidneys, despite a negligible amount of nanoparticles found in renal tissues.

Conclusion: Our data suggest, that although AuNPs belong to the safest nanomaterial platforms nowadays, due to their slow tissue elimination leading to long-term accumulation in the biological systems, they may induce toxic responses in the vital organs, and so understanding of their long-term biological impact is important to consider their potential therapeutic applications.

Keywords: AuNPs; biodistribution; fibrosis; in vivo; inflammation; long-term accumulation.

MeSH terms

  • Animals
  • Gold* / administration & dosage
  • Gold* / chemistry
  • Gold* / pharmacokinetics
  • Gold* / toxicity
  • Kidney* / drug effects
  • Kidney* / metabolism
  • Liver* / drug effects
  • Liver* / metabolism
  • Male
  • Metal Nanoparticles* / administration & dosage
  • Metal Nanoparticles* / chemistry
  • Metal Nanoparticles* / toxicity
  • Mice
  • Particle Size
  • Serum Albumin, Bovine* / chemistry
  • Serum Albumin, Bovine* / pharmacokinetics
  • Spleen* / drug effects
  • Tissue Distribution

Substances

  • Gold
  • Serum Albumin, Bovine

Grants and funding

This work was supported by the Slovak Research and Development Agency under Contract No. APVV-16-0579 and APVV-20-0494, and by VEGA grant no. 2/0116/22.